FDA Issues Complete Response Letter For Novo Nordisk's Weekly Basal Insulin Icodec
11/7 02:49
(RTTNews) - Novo Nordisk said that the US Food and Drug Administration has issued a Complete Response Letter or CRL covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus....